Progyny Toekomstige groei

Future criteriumcontroles 3/6

Progyny zal naar verwachting groeien in winst en omzet met respectievelijk 19.4% en 9.5% per jaar. De winst per aandeel zal naar verwachting groeien met 19.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.3% zijn.

Belangrijke informatie

19.4%

Groei van de winst

19.3%

Groei van de winst per aandeel

Healthcare winstgroei	20.9%
Inkomstengroei	9.5%
Toekomstig rendement op eigen vermogen	17.3%
Dekking van analisten	Good
Laatst bijgewerkt	29 Sep 2024

Recente toekomstige groei-updates

Recent updates

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Oct 21

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Oct 15

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18

Winst- en omzetgroeiprognoses

NasdaqGS:PGNY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,418	94	209	214	7
12/31/2025	1,217	66	183	188	10
12/31/2024	1,173	60	157	166	10
6/30/2024	1,133	63	171	174	N/A
3/31/2024	1,108	61	190	194	N/A
12/31/2023	1,089	62	185	189	N/A
9/30/2023	1,033	52	199	203	N/A
6/30/2023	957	49	165	169	N/A
3/31/2023	873	43	109	113	N/A
12/31/2022	787	30	77	80	N/A
9/30/2022	700	42	35	38	N/A
6/30/2022	617	46	38	41	N/A
3/31/2022	551	56	12	14	N/A
12/31/2021	501	66	24	26	N/A
9/30/2021	473	90	22	24	N/A
6/30/2021	450	78	14	15	N/A
3/31/2021	386	58	24	25	N/A
12/31/2020	345	46	35	36	N/A
9/30/2020	310	3	21	24	N/A
6/30/2020	272	-10	11	15	N/A
3/31/2020	264	-5	13	17	N/A
12/31/2019	230	-9	-4	-2	N/A
9/30/2019	194	-6	7	8	N/A
6/30/2019	160	1	1	2	N/A
3/31/2019	130	-4	0	0	N/A
12/31/2018	105	-6	2	2	N/A
12/31/2017	49	-13	N/A	-9	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei PGNY ( 19.4% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van PGNY ( 19.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.6% per jaar).

Hoge groeiwinsten: De winst van PGNY zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van PGNY ( 9.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PGNY ( 9.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PGNY zal naar verwachting over 3 jaar laag zijn ( 17.3 %).

Progyny Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 14% to US$26.13

Consensus EPS estimates fall by 16%

Progyny, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024

Price target decreased by 7.1% to US$43.40

Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Recent updates

Progyny, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorates as stock falls 29%

Price target decreased by 14% to US$26.13

Progyny: Downgrading As Uncertainties Increase

Consensus EPS estimates fall by 16%

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Progyny, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024

Progyny, Inc. to Report Q2, 2024 Results on Aug 06, 2024

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

President notifies of intention to sell stock

Progyny: Recent Stock Decline Provides Buying Opportunity

Progyny, Inc. (NasdaqGS:PGNY) acquired Apryl GmbH.

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Progyny: No Change To Long-Term Outlook

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Price target decreased by 7.1% to US$43.40

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Progyny, Inc. to Report Q1, 2024 Results on May 09, 2024

Progyny, Inc., Annual General Meeting, May 23, 2024

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Executive Chairman exercised options and sold US$2.4m worth of stock

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Progyny: Long-Term Thesis Still Intact

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. Announces Executive Appointments

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Executive Chairman exercised options and sold US$5.5m worth of stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Progyny, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Consensus EPS estimates increase by 28%

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Progyny, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive Chairman exercised options and sold US$4.0m worth of stock

Executive Chairman exercised options and sold US$714k worth of stock

Executive Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$54k worth of stock

Consensus EPS estimates increase by 54%

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Raises Financial Guidance for the Full Year Ending December 31, 2023

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

CEO & Director exercised options and sold US$318k worth of stock

Consensus EPS estimates fall by 17%

Executive Chairman exercised options and sold US$4.0m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Investor sentiment deteriorates as stock falls 16%

Executive Chairman exercised options and sold US$3.5m worth of stock